Erythrocyte Complement Receptor 1 and Alzheimer Disease
NCT ID: NCT01565434
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2012-02-29
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Neurology Unit Clinical Registry
NCT05925621
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
NCT00594568
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
NCT00880347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SCREENING
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CR1 impact
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de REIMS
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mahmoudi R, Feldman S, Kisserli A, Duret V, Tabary T, Bertholon LA, Badr S, Nonnonhou V, Cesar A, Neuraz A, Novella JL, Cohen JHM. Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer's Disease. Int J Mol Sci. 2018 Jul 25;19(8):2175. doi: 10.3390/ijms19082175.
Mahmoudi R, Kisserli A, Novella JL, Donvito B, Drame M, Reveil B, Duret V, Jolly D, Pham BN, Cohen JH. Alzheimer's disease is associated with low density of the long CR1 isoform. Neurobiol Aging. 2015 Apr;36(4):1766.e5-1766.e12. doi: 10.1016/j.neurobiolaging.2015.01.006. Epub 2015 Jan 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA11014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.